Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 21 Lung Neoplasms 10 Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 6 Skin Neoplasms 6 Prostatic Neoplasms 5 Neoplasm Metastasis 5 Melanoma 5 Head and Neck Neoplasms 5 Urinary Bladder Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Renal Cell 4 Carcinoma, Merkel Cell 4 Breast Neoplasms 4 Sarcoma 3 Pancreatic Neoplasms 3 Mycosis Fungoides 3 Carcinoma, Squamous Cell 3 Carcinoma, Hepatocellular 3 Carcinoma, Basal Cell 3 Adenocarcinoma 3 Uterine Cervical Neoplasms 2 Triple Negative Breast Neoplasms 2 Thyroid Carcinoma, Anaplastic 2 Rectal Neoplasms 2 Oropharyngeal Neoplasms 2 Mouth Neoplasms 2 Mesothelioma, Malignant 2 Lymphoma, T-Cell 2 Lymphoma, Large-Cell, Anaplastic 2

Interventions

Surgical Procedures, Operative 2 Paclitaxel 2 Doxorubicin 2 Cyclophosphamide 2 Carboplatin 2 pertuzumab 1 liposomal doxorubicin 1 cemiplimab 1 atezolizumab 1 Trastuzumab 1 Radiotherapy 1 Magnetic Resonance Spectroscopy 1 Indocyanine Green 1 Anastrozole 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Invasive Breast Cancer × cemiplimab × Clear all

NCT04243616 2025-09-05

CemiHALT

Medical College of Wisconsin

Phase 2 Active not recruiting

Invasive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡